Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.55 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | PARG | Q86W56 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4595276 | 0.90 | HPGD (0.53) | KIF11P2RX3NR3C2KDM4EALDH1A1 | |
| SCHEMBL4594426 | 0.89 | TRPV1 (0.52) | NR3C2EPHX2NR1H4PPARA | |
| SCHEMBL4595516 | 0.85 | KIF11 (0.57) | KIF11P2RX3KDM4EALDH1A1LMNA | |
| SCHEMBL9977540 | 0.84 | P2RX3 (0.56) | P2RX3PPARGKDM4EALDH1A1HDAC1 | |
| SCHEMBL10234498 | 0.80 | P2RX3 (0.45) | P2RX3PPARGHDAC1HDAC8HDAC6 | |
| SCHEMBL4594535 | 0.78 | TRPV1 (0.54) | NR3C2EPHX2NR1H4 | |
| SCHEMBL9977523 | 0.78 | P2RX3 (0.50) | KIF11P2RX3PPARGKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL4594293 | 0.77 | P2RX3 (0.49) | KIF11P2RX3PPARGKDM4EALDH1A1 | |
| SCHEMBL13656086 | 0.77 | KIF11 (0.89) | KIF11NR3C2KDM4EALDH1A1LMNA | |
| SCHEMBL4595750 | 0.74 | KIF11 (0.56) | KIF11KDM4EALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207182-B2 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2012-06-26 | — | — | US | claimed |
| EP-1874733-B1 | SUBSTITUTED CYCLIC UREA DERIVATIVES AND THE USE THEREOF AS VANILLOID RECEPTOR 1 MODULATORS | GRUENENTHAL GMBH (DE) | 2012-06-20 | — | — | EP | claimed |
| US-20080090855-A1 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2008-04-17 | — | — | US | claimed |
| EP-1874733-A1 | SUBSTITUTED CYCLIC UREA DERIVATIVES AND THE USE THEREOF AS VANILLOID RECEPTOR 1 MODULATORS | Grünenthal GmbH (DE) | 2008-01-09 | — | — | EP | claimed |
| WO-2006111346-A1 | SUBSTITUTED CYCLIC UREA DERIVATIVES AND THE USE THEREOF AS VANILLOID RECEPTOR 1 MODULATORS | Grünenthal GmbH (DE) | 2006-10-26 | — | — | WO | claimed |
| US-8207182-B2 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-1874733-B1 | SUBSTITUTED CYCLIC UREA DERIVATIVES AND THE USE THEREOF AS VANILLOID RECEPTOR 1 MODULATORS | GRUENENTHAL GMBH (DE) | 2012-06-20 | — | — | EP | disclosed |
| EP-1874733-B1 | SUBSTITUTED CYCLIC UREA DERIVATIVES AND THE USE THEREOF AS VANILLOID RECEPTOR 1 MODULATORS | GRUENENTHAL GMBH (DE) | 2012-06-20 | — | — | EP | disclosed |
| US-20080090855-A1 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| EP-1874733-A1 | SUBSTITUTED CYCLIC UREA DERIVATIVES AND THE USE THEREOF AS VANILLOID RECEPTOR 1 MODULATORS | Grünenthal GmbH (DE) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006111346-A1 | SUBSTITUTED CYCLIC UREA DERIVATIVES AND THE USE THEREOF AS VANILLOID RECEPTOR 1 MODULATORS | Grünenthal GmbH (DE) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090855-A1 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | TRPV1, TRPA1, P2RX3 | KIF11 4607/4885P2RX3 3/4885NR3C2 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.